Rare genetic variants make significant contributions to human diseases. Compared to common variants, rare variants have larger effect sizes and are generally free of linkage disequilibrium (LD), which makes it easier to identify causal variants. Numerous methods have been developed to analyze rare variants in a gene or region in association studies, with the goal of finding risk genes by aggregating information of all variants of a gene. These methods, however, often make unrealistic assumptions, e.g. all rare variants in a risk gene would have non-zero effects. In practice, current methods for gene-based analysis often fail to show any advantage over simple single-variant analysis. In this work, we develop a Bayesian method: MIxture model based Rare variant Analysis on GEnes (MIRAGE). MIRAGE captures the heterogeneity of variant effects by treating all variants of a gene as a mixture of risk and non-risk variants, and models the prior probabilities of being risk variants as function of external information of variants, such as allele frequencies and predicted deleterious effects. MIRAGE uses an empirical Bayes approach to estimate these prior probabilities by combining information across genes. We demonstrate in both simulations and analysis of an exome-sequencing dataset of Autism, that MIRAGE significantly outperforms current methods for rare variant analysis. In particular, the top genes identified by MIRAGE are highly enriched with known or plausible Autism risk genes. Our results highlight several novel Autism genes with high Bayesian posterior probabilities and functional connections with Autism. MIRAGE is available at https://xinhe-lab.github.io/mirage.
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different proportion of risk variants, with deleterious groups having higher risk proportions. To better 49 estimate these risk proportions, we pool information across all genes being analyzed using a Bayesian 50 hierarchical model. This strategy allows us to effectively account for uncertainty in estimating the effect 51 of risk variants and puts more emphasis on variants with putative functional effects. especially important when no individual genes pass the threshold in rare variant association tests, which 73 is often the case in exome sequencing studies. Statistical testing of variant sets is often accomplished by 74 so-called Burden test, such as Fisher's exact test, which compares variant counts in cases vs. controls. 75 MIRAGE-VS takes a different approach to variant set analysis. It is motivated by the observation that, 76 if the proportion of risk variants is low, we may not see significant difference in the total variant counts 77 between cases or controls. Thus MIRAGE-VS explicitly models all variants in the input set as a mixture 78 of risk and non-risk variants, and tests if the fraction of risk variants is greater than 0 ( Figure 1A) . 79 Specifically, for the j-th variant, let X j and T j be its allele count in cases and total allele counts in 80 cases and controls, respectively. If j is not a risk variant, X j given T j follows binomial distribution with 81 probability determined by case and control sample sizes (N 1 and N 0 ). If j is a risk variant, X j 82 conditioned on T j follows binomial distribution, with the parameter determined by both the effect of the 83 variant and sample sizes. Let Z j be an indicator of whether j is a risk variant, and we denote the prior 84 probability that j is a risk variant as P (Z j ) = η. We can write the model as:
where γ j is the relative risk of variant j (γ j > 1 for disease predisposing variants), modelled as a Gamma 86 distribution with meanγ. Our model defines a likelihood function of η, and we use the Expectation 87 Maximization (EM) algorithm [23] to estimate η given variant counts. We then test if η = 0 using 88 likelihood ratio test ( Figure 1A ). We note that the hyperprior parameterγ is not estimated, but treated 89 as a user-defined parameter. In our simulation and analysis, we use values between 3 and 7, informed 90 from analysis of exome sequencing studies [19, 24] , though simulations show that MIRAGE-VS is quite 91 robust to the exact values ofγ. 92 The full MIRAGE differs from MIRAGE-VS in two ways: first, a gene may consist of variants from 93 multiple functional categories, e.g. rare loss-of-function (LoF) variants or conserved missense variants. 94 The proportions of risk variants in these categories may vary substantially. Second, it is difficult to 95 estimate the values of η for all categories using data from a single gene because of sparsity of some of 96 these categories (e.g. a gene may have a single rare LoF variant). This motivates a hierarchical modeling 97 strategy, as we described below. 98 The input data of MIRAGE consist of case and control counts of all rare variants across all genes being 99 analyzed ( Figure 1B ), which could be all genes in the genome, or a subset of genes believed to be non-risk variants. For a risk gene, any of its variants has a prior probability of being a risk variant, with 107 the probability equal to η c if the variant belongs to the category c. We assume η c are shared among 108 variants in the category c of all risk genes. The full details are described in Methods. 109 MIRAGE first estimates the parameters, including δ and η c for all categories, by maximizing likelihood 110 over the entire dataset of all genes ( Figure 1B) . Then for each gene, it assesses its evidence of association 111 with the phenotype using all its variants by computing its Bayes factor (BF). BF is similar to likelihood 112 ratio test, comparing the null model (non-risk gene) and the alternative model (risk gene). BF of a gene 113 naturally combines the evidence of all its variants, with larger contributions from more functionally 114 important categories (those with larger values of η c ). Multiple testing is controlled by a Bayesian False 115 Discovery Rate (FDR) approach [25] .
116

MIRAGE-VS improves variant set analysis in simulations 117
We first use simulations to assess the performance of MIRAGE in detecting the presence of risk variants, 118 in a given variant set, mimicking the gene set analysis commonly used in practice. We simulate Figure 9 ). To compare the power of the three 136 methods, we generated simulated data under η = 0.1, 0.2, 0.3, with other parameters the same as before. 137 As we expect, the power at p < 0.05 increases at larger sample sizes and η. In all parameter settings,
138
MIRAGE-VS has significantly higher power than burden test and SKAT-O ( Figure 2 ).
139
In simulations above, we assumed that MIRAGE-VS knows the true value ofγ, the prior mean of 140 relative risk, used in generating the simulated data. To evaluate the effect of mis-specifiedγ, we 141 performed sensitivity analysis in the studies of both type I error and power. We setγ = 5 in simulations, 142 but usedγ = 3, 4, 5, 6 in MIRAGE-VS. Type I error of MIRAGE-VS is robust to mis-specified values of 143 γ ( Figure 10 ). Similarly, the power of MIRAGE-VS does not vary significantly with the value ofγ, and 144 remains higher than Burden test and SKAT-O in all settings even if it uses mis-specified value ofγ 145 ( Figure 11 ). The robustness of MIRAGE toγ is perhaps not surprising, as the value is only used in 146 specifying the prior distributions of variant effects. Indeed, the distributions under different values ofγ 147 overlap significantly.
148
MIRAGE is more powerful in identifying risk genes than existing methods 149 in simulations 150 We next perform simulations that mimic a real exome sequencing study with the goal of identifying 151 specific risk genes. We fix sample sizes at N 1 = N 0 = 3000. We simulate data of 1000 genes, with the variations of burden test, including Burden (baseline version), CMC [10] and ASUM [27] . In practice,
163
Burden test is often applied to different categories of variants of a gene separately to increase the power. 164 We thus consider two other versions of burden test as well, including Burden-adj which tests each of the 165 three categories separately, and returns the minimum p value of three tests; and Burden-combine which 166 combines three p values by Fisher's method. The results of these two tests in simulations, however, are 167 very similar to the baseline Burden test (Suppl. Figure 12 ), so we consider only the baseline version here. 168 We compare the performance of the methods in distinguishing risk from non-risk genes, using the ROC 169 curves ( In practice, when applying MIRAGE for gene discovery, it would be desirable to control the false 176 discovery rate (FDR). MIRAGE does this by using a Bayesian FDR approach that converts BFs to 177 posterior probabilities. We thus perform additional simulations to assess if the Bayesian FDR is 178 calibrated, and whether the FDR is sensitive to mis-specification ofγ. To make simulations simpler, we 179 run similar simulations as before, but use a common value ofγ for all three variant categories. For each 180 true value ofγ, ranging from 3 to 6, we used the true value and three mis-specified values ofγ in 181 MIRAGE, and computed Bayesian FDR. Our results show that Bayesian FDR are generally close to true 182 FDR and only slightly inflated when trueγ is large (greater than 5) (Suppl. Figure 13 ).
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MIRAGE-VS identifies variant sets associated with ASD 184
We applied MIRAGE to whole exome sequencing (WES) data of 4315 trios of parents and children 185 affected with ASD. Following a method we developed earlier for analyzing trio-sequencing data, we treat 186 transmitted alleles as "case" and non-transmitted ones as "controls" [19] . Risk variants are expected to 187 be transmitted more often than expected (1/2 by chance). We note that the transmission data naturally 188 avoids population structure that may confound case-control comparison. We consider only rare variants 189 with allele frequency (AF) below 5% in our analysis. Additionally, we filter all synonymous variants from 190 analysis except those close to exon-intron boundaries. 191 We first annotate the functional features of variants using ANNOVAR [28] . We identify loss-of-function 192 (LoF) variants as the union of stop loss, stop gain, frameshift indels and splice site substitutions. For 193 missense variants, we use PolyPhen, CADD and SIFT to define likely deleterious variants (PolyPhen 194 score greater than 0.957, CADD score top 10% or SIFT score < 0.05) [29] [30] [31] . For comparison, we also 195 include "non-damaging" variants according to PolyPhen (score less than 0.957), as a variant annotation. 196 Since AFs of variants are highly informative of deleteriousness of variant effects [32] , we also stratify 197 variants by their AFs in ExAC [33] . 198 We perform variant set analysis using MIRAGE. In addition to the variant level features described 199 above, we have gene-level features for variants. We use 10 gene sets that have been implicated as 200 potentially involved in ASD. Combining variant annotations, MAFs and gene-level features, we define a 201 total of 5 × 3 × 10 = 150 overlapping variant sets ( Figure 14 ). 202 We run MIRAGE-VS on each of the 150 variants sets, testing if the fraction of risk variants is greater 203 than 0 ( Figure 4 ). For comparison, we also perform the Burden test. At the Bonferroni threshold Table S ? for complete result). Notably, a number of significant sets from MIRAGE are missense 207 variants, which are generally more difficult to study than LoF variants and are completely missed by the 208 burden test ( Figure 4 ). These results thus highlight the substantially higher sensitivity of MIRAGE-VS 209 to identify variant sets associated with diseases, than the standard Burden test. 210 We observed several broad trends from the variant set results (Figure 4 ), largely consistent with what 211 we expect. Most of the sets with large η (fraction of risk variants) are LoF variants. Significant missense 212 variant sets, in contrast, have very low fractions of risk variants, generally below 5% ( Figure 4 ). This 213 highlights the sparsity of risk variants, even among those deemed deleterious by bioinformatic tools.
214
Additionally, all high confidence missense variant sets have very low AF (< 0.1%), confirming the 215 importance of using AF to prioritize risk variants. Comparing variant sets that differ only in PolyPhen 216 annotation (damaging vs. non-damaging), we notice that the annotation generally improves statistical 217 significance of top missense variant sets ( Figure 4 ).
218
MIRAGE identifies putative risk genes of ASD
219
While variant set analysis above demonstrates that MIRAGE is able to highlight some candidate variant 220 and gene sets associated with ASD, our ultimate goal is to find specific risk genes of ASD. Given the 221 relatively small sample size of the current study, we focus on a set of 1003 most constrained genes (top 222 10% by pLI scores) that are known to be enriched with ASD risk genes [34] . This allows us to enhance 223 the signal and reduces the burden of multiple testing. For each gene in this set, we divide their variants 224 into eight non-overlapping categories by combining functional effects and AFs. These include two LoF 225 categories (0.01 < AF < 0.05 and AF < 0.01), and six missense categories combining two functional 226 groups (damaging and non-damaging by PolyPhen) and three AF categories (0.01 < AF < 0.05, 227 0.001 < AF < 0.01 and AF < 0.001). 228 We first confirm that the ASD data is challenging for current methods, even after we limit to highly 229 constrained genes. We applied Burden test and SKAT-O on each of the 1003 genes. The QQ plots of p 230 values show that neither method is able to detect any significant gene ( Figure 5A and B). Indeed, none 231 of the genes would pass any meaningful FDR threshold (say 0.3). We also perform burden and SKAT-O 232 tests on the subsets of variants that are likely deleterious, including LoF and damaging variants (by PolyPhen). The QQ plots show essentially the same pattern (Suppl. Figure 15 ). 234 We then applied MIRAGE to this gene set. MIRAGE estimates that about 18% of these genes are ASD 235 risk genes ( Figure 5C ). MIRAGE also estimates the proportion of risk variants in each of the eight 236 variant categories ( Figure 5C ). The category of LoF variants with low AF (< 10 −2 ) shows the highest 237 proportion at 40%. And very rare missense variants (AF < 0.001) also show non-zero proportions at 238 around 15%. Somewhat unexpectedly, the proportions are similar between damaging and non-damaging 239 groups. With the estimated parameters, we calculated Bayes factor for every gene and perform Bayesian 240 FDR control. At F DR < 0.2, MIRAGE is able to identify three genes. This number increases to nine at 241 a more relaxed threshold of F DR < 0.3. These results thus support much higher sensitivity of MIRAGE 242 in detecting risk genes, comparing with current methods in use. 243 We evaluate the findings using two sources of ASD risk genes, all independent of the data we used in 244 this study. We focus on the top 10 genes by MIRAGE (posterior probability of risk genes > 0.5). The 245 statistical evidence and supporting information are provided in Table 1 . None of these genes show any 246 evidence by Bruden and SKAT-O tests. The majority of these 10 genes are involved in ASD, according 247 to SFARI Gene [35] . CHD8 and TRIP12 are known ASD genes (SFARI score 1S). SRCAP and 248 CACNA1D are strong candidates of ASD (score of 2). Four other genes show suggestive evidence (score 249 of 3), including CYFIP1, EP400, FBN1 and DYNC1H1. We found strong evidence of enrichment of 250 SFARI ASD genes in this list, comparing with all 1003 constrained genes ( Figure 5D ). Even two 251 remaining genes not curated by SFARI Gene show some connection with ASD. DOCK4 is a component 252 of Wnt signaling, a key pathway of neurodevelopment. DOCK4 has been associated with ASD and 253 Schizophrenia [36, 37] . ABCA2 has been implicated as a candidate gene of Schizophrenia from multiple 254 lines of evidence [38] . We also assess the connection of these genes with ASD using a list of top 1000 255 genes ranked by TADA using de novo mutations (DNMs [26] ). Comparing with all 1003 genes, our list is 256 highly enriched with DNM candidate genes ( Figure 5D ). These independent evidence thus strongly 257 Furthermore, it provides a framework to assess functional annotations in prioritizing deleterious variants, 280 and to leverage these annotations in identifying risk genes. We provide two implementations of 281 MIRAGE, MIRAGE-VS for detecting burden in variant set analysis and MIRAGE full version for 282 identifying specific risk genes. This makes it flexible for researchers to use MIRAGE in different ways.
283
Simulations under various scenarios confirm the effectiveness of our method. In application to a WES 284 dataset of ASD, we find that MIRAGE-VS is much better at identifying the presence of risk variants in 285 various gene sets than the standard burden analysis. At the level of individual genes, even though 286 current methods fail to find any signal, the results of MIRAGE are highly enriched with ASD risk genes, 287 confirmed by independent evidence.
288
How to effectively analyze rare variants is a key challenge of the field. The success of MIRAGE in the 289 study of ASD allows us to draw some general lessons that will help address this challenge. First, the 290 effects of rare variants are likely very heterogeneous, and this is better captured by a sparse model where 291 most rare variants have no effects on disease risk. One can see this point clearly from our low estimated 292 fractions of risk variants (Figures 4 and 5C) , and from the analysis of individual gene ( Figure 6 ). Our 293 observation is contrary to a common, implicit belief in developers of rare variant association test, that in 294 a risk gene, all rare variants tend to have some effects. Secondly, using external information of variants is 295 critical to improve the signal to noise ratio. In particular, allele frequencies from large population 296 reference are very helpful in separating functional from non-functional variants (Figures 4 and 5C ).
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Variant annotation is an active area of research, and we think some recent methods, e.g. those based on 298 deep learning, may further boost the power of MIRAGE [42] . Finally, to identify specific disease genes, it 299 would be helpful to focus on a set of genes that are enriched with putative risk genes. In our study of 300 ASD, we limit our analysis to 1,003 constrained genes. We suggest a possible strategy for future studies: 301 first use MIRAGE-VS to learn gene sets with burden signals, then take the union of these genes for full 302 MIRAGE analysis. 303 We find that the ASD genes we identified using inherited rare variants are often supported by 304 independent evidence, particularly from studies using de novo mutations (DNMs stratification is of particular concern as it may lead to false positive findings. It is generally difficult to 322 address this issue in generative models such as MIRAGE. One possible strategy is to regress out all the 323 sample covariates, and treat the residuals as quantitative traits so that we can reduce the covariate case-control samples, with sample sizes N 1 (cases) and N 0 (controls). We denote X j and X (0) j the 334 number of rare alleles of variant j in cases and in controls, respectively. We also denote T j = X j + X (0) j 335 the total allele count. MIRAGE-VS models these variants as a mixture of risk and non-risk variants. Let 336 Z j be an indicator of whether the variant j is a risk variant (Z j = 1) or not (0). Z j follows Bernoulli 337 distribution with mean η. The goal of MIRAGE-VS is to estimate η and test if it is equal to 0.
338
For a rare variant, its allele count in a set of samples can be described by a Poisson distribution. We 339 denote q j the allele frequency of variant j in controls. If j is a non-risk variant (Z j = 0), its allele 340 frequency in cases would also be q j . So we have:
If j is a risk variant (Z j = 1), its allele frequency in cases would generally be elevated. Let γ j be the fold 342 increase of allele frequency. It can be interpreted as the relative risk of variant j, as shown in [19] . So we 343 have:
It is generally difficult to estimate γ j for individual rare variants, so following TADA [19] , we treat γ j as 345 random, following Gamma(γ, σ). The hyper-parameterγ is the prior mean of relative risk of risk 346 variants, and σ is the dispersion parameter. 347 We note that q j is a nuisance parameter of no primary interest. So we take advantage of the property 348 of Poisson distribution that the conditional Poisson random variable follows Binomial distribution. This 349 PLOS 12/27 allows us to eliminate q j :
We marginalize γ j in evaluating the probability of allele counts for risk variants:
The full model can be shown as a probabilistic graphical model ( Figure 7A ). We assume the 352 hyperparameters are given. Let X be the vector of X j for all variants and T be the vector of T j 's. The 353 likelihood function of η is given by:
where we assume the variants are independent. Since we focus on variants with AF < 5%, this 355 assumption is generally valid.
356
The parameter estimation is performed by Expectation Maximization (EM) algorithm [23] . The details 357 are provided in the Supplementary Notes. Once we have maximum likelihood estimation (MLE) of η, we 358 test if η = 0 by the likelihood ratio test (LRT). The p-value of the test is determined from the χ 2 359 distribution.
360
MIRAGE model 361
The full MIRAGE model differs from MIRAGE-VS in two ways. First, it analyzes the data of a large 362 number of genes (potentially the whole exome). Only a subset of these genes are risk genes. Secondly, a 363 single risk gene may have multiple distinct variant groups, with different values of η (proportion of risk 364 variants). For instance, the LoF variants of a risk gene probably are more enriched with risk variants 365 than its missense variants. We assume each variant belongs to one of multiple, disjoint, categories.
366
MIRAGE model is shown as a probabilistic graphical model in Figure 7B . We denote U i the indicator 367 of whether gene i is a risk gene. U i is a Bernoulli random variable with mean δ. For variant j of gene i, 368 we denote X ij its rare allele count in cases and T ij its total allele counts in cases and controls. Each Similar to the description of MIRAGE-VS model above, we denote X and T as the set of allele counts 378 in cases, and in cases and controls combined. We also denote C as the set of variant annotations c ij 's.
379
Our primary parameters of interest are δ, the proportion of risk genes, and η, the vector of η c 's for all 380 variant categories. The likelihood function is given by:
where X i , T i , C i are the relevant data of all variants in gene i. The first probability term in the equation 382 is the likelihood of a non-risk gene, and is simply given by:
The second probability term is the likelihood of a risk gene:
where P (X ij |T ij , Z ij = 1) is given by Equation (5) (adding gene index i in that equation, adding index i 385 only in that single equation could be confusing, unless in the whole section, so do you want to do that?). 386 The parameters δ and η are estimated by EM algorithm (see EM Algorithm in the Supplements).
387
Given the MLEδ andη, we can determine the Bayes factor of a gene i, B i , and its posterior probability 388 of being a risk gene, PP i , as:
It is easy to show that B i can be related to the evidence at the single variant level:
where B ij is the BF of variant j of gene i. From this equation, one can see that the more deleterious 391 variant categories with larger values of η c will contribute more to the gene level evidence.
392
Once we determine BF and posterior probability of all genes, we control for multiple testing by 393 performing Bayesian FDR control [19] .
394
Simulation procedure 395 Simulation for MIRAGE-VS analysis: We simulate case-control counts of a variant set, for given sample 396 sizes (N 1 and N 0 for cases and controls, respectively) and given proportion of risk variants η. For each 397 variant in the set, we repeat the following steps. (1) We sample the risk variant status Z j for variant j (1 398 if it is a risk variant, and 0 otherwise): Z j ∼ Bernoulli(η). And if Z j = 1, we also sample the relative 399 risk γ j ∼ Gamma(γ, σ). Bothγ and σ are set as user-specified parameters. We use σ = 1 in the paper in 400 all simulations. (2) We sample the allele frequency q j from a Beta distribution. If Z j = 0, we sample 401 from Beta(α 0 , β 0 ). We set α 0 = 0.1, β 0 = 1000 in our simulations. If Z j = 1, we assume variants would 402 PLOS 14/27 be even rarer, so we sample from Beta(α, β), where α = 0.1, β = 2000 (so mean AF is two times lower 403 than non-risk variants). (3) We sample the total allele count in the data by T j ∼ Pois(N 1 + N 0 , q j ). It is 404 possible that T j is 0, and such variants are filtered. (4) We split the total variant count T j into cases and 405 controls by Binomial distribution. If Z j = 0, we split the count according to sample sizes, so the 406 probability in cases is equal to N 1 /(N 1 + N 0 ). If Z j = 1, the probability in cases is
N1γj
N1γj +N0 .
407
Simulation for MIRAGE analysis: We simulate a set of genes under given case-control sample sizes 408 N 1 , N 0 and the proportion of risk genes δ. We assume each gene has a mixture of variants in different 409 categories, with fixed proportions of variant categories. In the simulations of the paper, we use three 410 categories mimicking LoF, deleterious missense variants and the rest, with fractions 10%, 30% and 60% 411 respectively. Each category is allowed to have different mean relative risksγ and different proportion of 412 risk variants, η c for category c. We useγ = 5 for LoF and 3 for missense categories, and η c 0.5, 0.2 and 413 0.05 for the three categories, respectively. Our simulation starts with sampling the risk status for gene i, 414 U i ∼ Bernoulli(δ). When U i = 0, all variants would be non-risk variants. When U i = 1, we sample the Rubies et al [24] , provided by Autism Sequencing Consortium.
421
Annotating variants
422
The software package annovar was used to query the dbNSFP database of functional effect predictions. 423 We annotate with several popular programs including PolyPhen, CADD and SIFT [29] [30] [31] . This suite of 424 generic variant annotations was then augmented with 10 gene sets associated with a variety of 425 neuropsychiatric traits (listed in Figure 14 ). High confidence ASD and moderate confidence ASD genes 426 are defined by the q-values of TADA analysis [19, 26] , using q < 0.1 and 0.1 ≤ q < 0.3, respectively. The 427 other gene sets are collected from literature (with PMIDs listed in the figure). All the 10 gene lists can 428 be found in Supplementary Table ? 429
Applying MIRAGE to ASD data 430 For MIRAGE-VS analysis of variant sets, we analyze each variant set separately. The hyperprior 431 parameter for relative risk,γ, is set at 6 for LoF and 3 for missense variant sets. In the EM algorithm for 432 estimating the parameter η, the fraction of risk variants, we randomly choose initial values, and the 433 algorithm converges if the change of parameter estimates in two iterations is less is less than 10 −5 .
434
For MIRAGE analysis of 1003 constrained genes, we create 8 variant categories as described in Results. 435 We use the same hyperprior parameter for LoF and missense variants, as described above. The EM 436 algorithm is used to estimate δ, the proportion of risk genes, and η c , the percent of risk variants for each 437 category c. Running of EM is similar as above. Once these parameters are estimated, their values are 438 assumed to be known, and are used in calculating BF of each gene. Methods. For simplicity of notation, we drop T or T j in the probability or conditional probability terms. 450 We assume the hyperprior parametersγ and σ are given, so we also drop them in the notations. We note 451 though it is possible to estimate the hyperparameters by ML. We denote θ = (η) as parameter of interest 452 and θ (t) as its value in the t-th iteration (this is for generality, as θ would represent a set of parameters 453 in full MIRAGE). 454 We denote B j as the BF of variant j:
where the two probabilities are given by Equations (4) and (5) .
456
• E step: calculating the expectation of the log likelihood conditioned on the observed data and θ (t) . 457
where π j (η) = P (Z j = 1|x j , η), is the posterior probability that variant j is a risk variant.
458
The derivations are based on:
where B j is given in (13) .
= c j (θ (t) )B j (θ (t) )π j (η (t) ) π j (η (t) )c j (θ (t) )B j (θ (t) ) + (1 − π j (β (t) ))c j (θ (t) ) = π j (η (t) )B j (θ (t) ) π j (η (t) )B j (θ (t) ) + (1 − π j (η (t) )) Denote c j = P (x j |Z j = 0, θ). Then P (x j |Z j = 1, θ) = c j B j . B j is the Bayes factor for variant j.
460
• M step updates θ by θ (t+1) that maximizes Q(θ|θ (t) ). That is
Then, taking derivatives leads to
Setting these equations equal to 0 yields
where J is the total number of variants in a variant set. For parametersγ, σ, there are no closed 462 form solutions forγ (t+1) , σ (t+1) . Instead, we fixγ, σ.
463
EM for MIRAGE Let θ denote all parameters and θ (t) be the parameter estimate at the tth 464 iteration.
465
• E step: calculates the expectation of the log likelihood of parameter θ conditional on the observed data and θ (t) .
Q(θ|θ (t) ) = E U,Z|X,θ (t) log L(θ|x, U, Z) = E U,Z|X,θ (t) log(P (x, U, Z|θ)) = E U,Z|X,θ (t) log(P (U, Z|θ)) + E U,Z|X,θ (t) log(P (x|U, Z, θ))
where δ = P (U i = 1|θ). The last equation holds because log(P (U, Z|θ)) = log(P (U |θ) × P (Z|U = 1, θ))
and P (x|U, Z, θ) = Denote d i = P (x i |U i = 0, θ). Hence gene i is non-risk gene and d i should be Binomial probability with γ = 1, then P (
Note at gene level, Z ij is useless. B i is the Bayes factor for gene i. Thus
When gene i is a causal gene, i.e. U i = 1, the likelihood can be decomposed further into variant level
where B ij is the Bayes factor for j-th variant in i-th gene and π ij (η) = P (Z ij = 1|U i = 1, η). Combining together across all the genes yields
c is a constant free of parameters. Now look at expectation terms,
Note here x ij is the counts of only cases. So we consider the conditional distribution of
Because
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Taking derivatives with respect to θ leads to
Suppose there are C annotation groups. η = (η 1 , η 2 , · · · , η C ) is a vector. The variant (i, j) belonging to group c has the prior probability of being causal π ij (η) = η c with group prior. Use v(i, j) = c to denote variant (i, j) in group c.
I is the total number of genes.
For parametersγ, σ, there are no closed solutions forγ (t+1) , σ (t+1) . Instead, we fixγ, σ based on 468 empirical evidence. 
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Observed − log 10 (p−values) (A) Burden
